RT Book, Section
A1 Cantilena, Louis R.
A2 Hoffman, Robert S.
A2 Howland, Mary Ann
A2 Lewin, Neal A.
A2 Nelson, Lewis S.
A2 Goldfrank, Lewis R.
SR Print(0)
ID 1108438511
T1 Drug Development, Adverse Drug Events, and Postmarketing Surveillance
T2 Goldfrank's Toxicologic Emergencies, 10e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 9780071801843
LK accesspharmacy.mhmedical.com/content.aspx?aid=1108438511
RD 2024/04/16
AB This  chapter  will  focus  on  drug-induced  diseases  that  occur  as  expected  or  unexpected  adverse  drug  events  (ADEs),  as  a  drug–drug  interaction  or  an  ADE  causing  an  untoward  drug–disease  interaction.  Also  included  in  this  chapter  is  a  discussion  of  an  approach  to  the  diagnosis  of  drug-induced  disease,  an  overview  of  the  new  drug  approval  process  in  the  United  States,  monitoring  of  drug  safety  postapproval,  and  the  suggested  role  for  the  ­medical  toxicologist  in  the  discovery,  reporting,  and  prevention  of  ADEs.